// App-Quantinova.ai

: CSF apolipoprotein B levels predict future visuospatial cognitive decline and synaptic pathology in cognitively unimpaired healthy elderly with a parental history of Alzheimer’s disease

Researchers

Presenter

  • Judes Poirier

Principal Investigators

  • Nathalie I.V. Nilsson

  • Anne Labonté

  • Pedro Rosa-Neto

  • Nicholas J. Ashton

  • Henrik Zetterberg

  • Kaj Blennow

  • John Breitner

  • Sylvia Villeneuve

  • Cynthia Picard

Medical Centers

  • McGill Center for Studies in Aging

  • Douglas Mental Health University Institute, Montreal

  • Centre for Studies on Prevention of Alzheimer's disease (StoP-AD Centre), Douglas Mental Health Institute

  • University of Gothenburg,

  • Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London

  • Douglas Research Centre

  • McGill University,

  • Institute of Neuroscience & Physiology, Department of Psychiatry & Neurochemistry, The Sahlgrenska Academy, University of Gothenburg

  • Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Moelndal, Sweden

  • Centre for Studies on Prevention of Alzheimer's disease (StoP-AD Centre)

  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Sweden

  • McGill University Faculty of Medicine

  • Douglas Mental Health Research Institute

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Mild cognitive impairment

  • Alzheimer's disease

Biomarkers

  • Apolipoprotein B

  • Apolipoprotein E

  • Cerebrospinal fluid

Drug/Treatment

  • Flutafuranol F18

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved